Improvement of conformal arc plans by using deformable margin delineation method for stereotactic lung radiotherapy

Görkem Güngör | Melek Demir | Gökhan Aydın | Bülent Yaıcı | Banu Atalar | Enis Özyar

Abstract

Purpose: Stereotactic body radiotherapy (SBRT) is an established treatment technique in the management of medically inoperable early stage non-small cell lung cancer (NSCLC). Different techniques such as volumetric modulated arc (VMAT) and three-dimensional conformal arc (DCA) can be used in SBRT. Previously, it has been shown that VMAT is superior to DCA technique in terms of plan evaluation parameters. However, DCA technique has several advantages such as ease of use and considerable shortening of the treatment time. DCA technique usually results in worse conformity which is not possible to ameliorate by inverse optimization. In this study, we aimed to analyze whether a simple method – deformable margin delineation (DMD) – improves the quality of the DCA technique, reaching similar results to VMAT in terms of plan evaluation parameters.

Methods: Twenty stage I–II (T1-2, N0, M0) NSCLC patients were included in this retrospective dosimetric study. Noncoplanar VMAT and conventional DCA plans were generated using 6 MV and 10 MV with flattening filter free (FFF) photon energies. The DCA plan with 6FFF was calculated and 95% of the PTV was covered by the prescription isodose line. Hot dose regions (receiving dose over 100% of prescription dose) outside PTV and cold dose regions (receiving dose under 100% of prescription dose) inside PTV were identified. A new PTV (PTV-DMD) was delineated by deforming PTV margin with respect to hot and cold spot regions obtained from conventional DCA plans. Dynamic multileaf collimators (MLC) were set to PTV-DMD beam eye view (BEV) positions and the new DCA plans (DCA-DMD) with 6FFF were generated. Three-dimensional (3D) dose calculations were computed for PTV-DMD volume. However, the prescription isodose was specified and normalized to cover 95% volume of original PTV. Several conformity indices and lung doses were compared for different treatment techniques.

Results: DCA-DMD method significantly achieved a superior conformity index (CI), conformity number (CIPaddick), gradient index (R50%), isodose at 2 cm (D2 cm) and external index (CA) with respect to VMAT and conventional DCA plans (P < 0.05 for all comparisons). CI ranged between 1.00–1.07 (Mean: 1.02); 1.00–1.18 (Mean: 1.06); 1.01–
1.23 (Mean 1.08); 1.03–1.29 (Mean: 1.15); 1.04–1.29 (Mean: 1.18) for DCA-DMD-6FFF, VMAT-6FFF, VMAT-10FFF DCA-6FFF and DCA-10FFF respectively. DCA-DMD-6FFF technique resulted significantly better CI compared to others ($P = 0.002; < 0.001; < 0.001; < 0.001$). $R_{50\%}$ ranged between 3.22–4.74 (Mean: 3.99); 3.24–5.92 (Mean: 4.15) for DCA-DMD-6FFF, VMAT-6FFF, respectively. DCA-DMD-6FFF technique resulted lower intermediate dose spillage compared to VMAT-6FFF, though the difference was statistically insignificant ($P = 0.32$). $D_2$ cm ranged between 35.7% and 67.0% (Mean: 53.2%); 42.1%–79.2% (Mean: 57.8%) for DCA-DMD-6FFF, VMAT-6FFF respectively. DCA-DMD-6FFF have significantly better and sharp falloff gradient 2 cm away from PTV compared to VMAT-6FFF ($P = 0.009$). $C\delta$ ranged between 0.052 and 0.140 (Mean: 0.085); 0.056–0.311 (Mean: 0.120) for DCA-DMD, VMAT-6FFF, respectively. DCA-DMD-6FFF have significantly improved $C\delta$ ($P = 0.002$). VMAT- $V_{20\ Gy}$, $V_{2.5\ Gy}$ and mean lung dose (MLD) indices are calculated to be 4.03%, 23.83%, 3.42 Gy and 4.19%, 27.88%, 3.72 Gy, for DCA-DMD-6FFF and DCA techniques, respectively. DCA-DMD-6FFF achieved superior lung sparing compared to DCA technique. DCA-DMD-6FFF method reduced MUs 44% and 33% with respect to VMAT-6FFF and 10FFF, respectively, without sacrificing dose conformity ($P < 0.001; P < 0.001$).

**Conclusions:** Our results demonstrated that DCA plan evaluation parameters can be ameliorated by using the DMD method. This new method improves DCA plan quality and reaches similar results with VMAT in terms of dosimetric parameters. We believe that DCA-DMD is a simple and effective technique for SBRT and can be preferred due to shorter treatment and planning time.

**PACS**
87.55.D-

**KEY WORDS**
DCA, FFF, SBRT, VMAT

---

1 | INTRODUCTION

SBRT is the delivery of a curative radiation dose to a visible gross tumor in a very precise way, using image guidance generally in 1 to 5 fractions.\textsuperscript{1–7} Early studies have shown that SBRT is an effective and well-tolerated treatment for early stage inoperable non-small cell lung cancer (NSCLC) patients.\textsuperscript{6–9} SBRT can be delivered with 4 different techniques; three dimensional conformal multiple static beams (3DC) with coplanar or noncoplanar fields, three-dimensional conformal arc (DCA), intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT). Each method has different advantages and disadvantages.

The DCA technique widely replaced 3DC techniques with its advantage of using large number of beam directions and shorter treatment time.\textsuperscript{10,11} Moreover, DCA plans have better conformity in three-dimensional complex target volume shapes, converging to quasi-sphere form can result because of better DCA conformity than 3DC plans.\textsuperscript{12} Moreover, since the dynamic field shape encompasses the target volume, DCA can avoid interplay effect because of shorter delivery time and continuous dynamic field openings during treatment delivery.\textsuperscript{12} Despite the interplay effect concern of intrafractional target volume motion, coplanar and noncoplanar inversely optimized IMRT techniques are also used safely in SBRT treatments.\textsuperscript{13–15} However, it is largely replaced by VMAT due to the shorter treatment delivery time and improved target dose conformity.\textsuperscript{16–18} Recent removal of flattening filter from the beam generation module increased dose rates 2.5 to 4 times for different photons energies. This led to significant shortening of the treatment delivery time for both DCA and VMAT techniques.\textsuperscript{19,20} FFF-based techniques recently became a standard treatment for SBRT.\textsuperscript{21–25} It has also been shown that VMAT-FFF has led to better conformity parameters with shorter treatment delivery time than 3DC, DCA, IMRT, and VMAT techniques.\textsuperscript{22–27}

There are similarities between DCA and VMAT techniques. Both techniques use arc method, and treatment times are significantly short. VMAT technique results in better conformity due to use of inverse optimization method during planning but with the cost of a longer time for planning process and quality assurance. However, it
is easy to generate DCA plan but difficult to achieve high dose conformity for complex shaped target volumes compared to VMAT. Therefore, several authors have investigated different modifications of DCA technique to improve the dose distributions with modification of either dynamic conformal technique or planning target volume (PTV).28–32 In this study, we investigated a simple method to ameliorate the dose conformity in patients treated with DCA technique. If our new method leads to better dose evaluation parameters than conventional DCA and reaches similar results to VMAT technique, it may considerably decrease the treatment planning time, increase dose conformity favorably and decrease treatment time.

2 MATERIALS AND METHODS

This retrospective dosimetric study included a total of 20 stage I–II (T1-2, N0, M0) NSCLC patients treated with SBRT in our department. Lesions were chosen to be representative of the most frequent type of stage I–II tumors diagnosed in the clinical setting. Therefore, the location, volume and size of the tumors investigated was heterogeneous (7 tumors are centrally and 13 tumors are peripherally located; 12 tumors are in the left and 8 tumors are in the right lung; 7 tumors are in the upper lobes and 13 tumors are in the lower lobes). Target volume and fractionation characteristics are summarized in Table 1.

All patients underwent four dimensional CT (4DCT) (Biograph 16, Siemens Medical Solutions, Erlangen Germany) scans with wing board arms up without vacuum cushion or abdominal compression. By obtaining 4D-CT, maximum-intensity projection (MIP) image sets were created and used to help define the internal target volume (ITV). Furthermore, PTV margin was delineated with an isotropic 5 mm expansion of ITV. Average intensity projection CT (AveIP-CT) was also created in order to perform three-dimensional dose calculations. In addition, organ at risk (OAR), such as left and right lung, chest wall, trachea, spinal cord, esophagus, heart, and great vessels were delineated in AveIP-CT.

**2.A Treatment planning and features**

For each patient, conventional DCA–FFF, VMAT–FFF and DCA–FFF with deformable margin delineation (DCA-DMD) method plans were generated, utilizing 6 MV and 10 MV photon energies for a TrueBeam STx linear accelerator (Varian Medical Systems, Palo Alto, CA, USA). The prescription isodose lines covering the 95% volume of PTV (VPTV) were normalized to 70%–85% of isodose line. Several dose constraints for different fractionations were used for different OARs which are summarized in Table 2.1,33–37

**2.B Dynamic conformal arc (DCA)**

Conventional DCA plans were generated, using 340° coplanar arcs in order to obtain acceptable coverage, field aperture size and shape corresponded identically to the projection of the PTV outline along the beam’s eye view. Each control point was dynamically adjusted during arc rotation according to radiation therapy oncology group (RTOG) 0915 protocol guidelines.33 Eclipse treatment planning system (TPS) was used with analytical anisotropic algorithm (AAA) dose calculation (v. 13.6.2) based upon 6 MV and 10 MV energies with FFF modality.

**2.C VMAT**

The VMAT plans were created, using commercial RapidArc module in Eclipse TPS with progressive resolution optimization (PRO3) (v. 13.6.2) solution. The PRO3 module was mainly based on direct aperture optimization approach varying with multileaf collimators (MLC), gantry speed and dose rate on each control point (CP).38 The PRO3 module proceeded through four phases at the same time. The full collection of 178 CPs was optimized in all four phases while

### Table 1 Target and fractionation characteristics.

| Characteristics | Value       |
|----------------|------------|
| ITV (cc)       |            |
| Mean           | 17.29      |
| Median         | 7.35       |
| Range          | 0.56–69.39 |
| PTV (cc)       |            |
| Mean           | 41.01      |
| Median         | 22.57      |
| Range          | 4.59–123.49|
| Fractionation scheme (Gy) | |
| 3 × 18         | 7 of 20    |
| 5 × 11         | 8 of 20    |
| 8 × 7.5        | 5 of 20    |

### Table 2 OAR constraints for different fractionation schemes.

| OAR               | Limit | 3 fractions | 5 fractions | 8 fractions |
|-------------------|-------|-------------|-------------|-------------|
| Chest wall        |       |             |             |             |
| V30 Gy cc         | 30    | 30          |             |             |
| V50 Gy cc         | 50    | 50          |             |             |
| V60 Gy cc         | 60    | 60          |             |             |
| Esophagus         |       |             |             |             |
| Dmax Gy          | 25.2  | 35          | 40          |             |
| D2 Gy cc         | 17.7  | 19.5        |             |             |
| Great vessels     |       |             |             |             |
| Dmax Gy          | 45    | 53          | 53          |             |
| D10 Gy cc        | 39    | 47          | 47          |             |
| Heart/pericardium|       |             |             |             |
| Dmax Gy          | 30    | 38          |             |             |
| D15 Gy cc        | 24    | 32          |             |             |
| Lungs             |       |             |             |             |
| V20 Gy cc        | 10%   | 10%         | 10%         |             |
| V2.5 Gy cc       | 30%   | 30%         |             |             |
| MLD Gy cc        | 10    | 10          |             |             |
| Spinal cord       |       |             |             |             |
| Dmax Gy          | 21.9  | 30          | 30          |             |
| V10% Gy cc       | 18    | 23          |             |             |
| V2.35 Gy cc      | 18    | 23          |             |             |
| V1.2 Gy cc       | 12.3  | 14.5        |             |             |
| Trachea           |       |             |             |             |
| Dmax Gy          | 30    | 40          | 44          |             |
dose calculation was still in progress. Each VMAT plan consisted of two coplanar arcs with clockwise and counter-clockwise rotation. Collimator rotation angles of arcs were 10° and 350°, respectively, with 0 mm MLC margin to the outline of PTV. Arc entrance through the contralateral healthy lung was restricted as much as possible. AAA (v 13.6.2) was used in order to obtain three-dimensional dose distributions for evaluation of 6 MV and 10 MV with FFF plans.

2.D Dynamic conformal arc with deformable margin delineation (DCA-DMD)

DCA plans usually result in nonconformal coverage. Undesired hot spot and cold spot dose regions around PTV and especially shift of high dose volume out of ITV are general problems for conventional DCA treatment plans (shown in Fig. 1).

Firstly, a conventional DCA plan with 6FFF was generated and 100% of prescription isodose line covering the 95% VPTV was normalized. The prescription isodose lines were specified with covering the 95% volume of PTV (VPTV) which were normalized to 70%–85% of isodose.

We identified dose regions outside the PTV receiving doses over 100% of prescription dose (as hot spots) and inside the PTV receiving a dose under 100% of prescription dose (as cold spots). The new PTV, deformable margin delineated PTV (PTV-DMD), was delineated with the help of deformation of PTV according to identified hot and cold spot dose regions, which were obtained from conventional DCA plan, toward either the negative or positive directions.

If a hot spot region was present outside the PTV, PTV-DMD was created by deformable shrinkage of PTV and if a cold spot region was present inside PTV, PTV-DMD was created by deformable expansion of PTV (shown in Fig. 2).

Finally, a new DCA plan with 6FFF photon energy (DCA-DMD plan) was generated, using PTV-DMD volume. 3D dynamic MLC positions were set to beam eye view of PTV-DMD and 3D dose calculations were computed for PTV-DMD volume. However, the prescription isodose was normalized to cover 95% volume of original PTV after 3D dose calculation.

2.E Evaluation of treatment planning dosimetric parameters

Target conformity and organ at risk (OAR) doses were compared for DCA (6FFF-10FFF), VMAT (6FFF-10FFF) and DCA-DMD (6FFF) planning techniques. Target conformity was evaluated by analyzing the following parameters: Dose to 2%, 50% and 98% volume of PTV (D2%, D50% and D98%), maximum dose of PTV (Dmax), conformity index (CI), conformity Paddick index (ClPaddick), homogeneity index (HI), ratio of 50% isodose volume to PTV volume (R50%), maximum relative isodose at any point 2 cm or further away from PTV (D2 cm) and external index (C). MU was considered for its treatment delivery efficiency. All plans were evaluated using RTOG 0915 prescription dose constraints for treatment planning guidelines and ICRU recommendations.

2.F Conformity index (CI)

The RTOG conformity index is defined as ratio of prescription isodose volume (Vr) to the PTV volume. Ideal value of CI is unity and generally it is greater than one.

\[
CI = \frac{V_{r}}{V_{PTV}}
\]

2.G Conformity Paddick index or conformity number (ClPaddick)

A new conformity index (ClPaddick) was proposed by Paddick as it does not produce false perfect scores. CI Paddick denoted as

\[
Cl_{Paddick} = \frac{TV_{PIV}}{TV} \cdot \frac{TV_{PV}}{PIV} = \frac{(TV_{PV})^2}{TV \cdot PIV}
\]

where TV, PIV are target volume and prescribed isodose volume, respectively, and TVPV is the volume of target covered by prescription isodose. ClPaddick can be described as the multiplication of conformity and selectivity of plan. The first fraction of this equation defines the quality of coverage of target; the second fraction defines the volume of healthy tissue receiving a dose greater than or
equal to the prescribed reference dose.\textsuperscript{44} Ideal value of CI\textsubscript{Paddick} is unity and generally less than one.

2.H | Gradient index (GI)

The ratio of 50% prescription isodose volume to the PTV volume is $R_{50\%}$.\textsuperscript{33} None and only minor deviations of $R_{50\%}$ were accepted while evaluating plans with respect to the PTV volume for SBRT plans according to RTOG 0915 protocol guidelines. Where this index value falls below none deviation, it refers to a sharp dose fall off around intermediate dose spillage region. Paddick I. and Lippitz B. proposed to use gradient index (GI) for SRS plans in 2006\textsuperscript{43}

$$R_{50\%} = \frac{V_{50\%}}{V_{PTV}}$$

(3)

2.I | Intermediate dose spillage location at 2 cm ($D_2$ cm)

Intermediate dose spillage location is defined as the maximum dose in percentage of dose prescribed at 2 cm away from PTV in any direction ($D_2$ cm).\textsuperscript{33}

2.J | Homogeneity index (HI)

The dose homogeneity of PTV,\textsuperscript{41} is described as

$$HI = \frac{(D_{2\%} - D_{98\%})}{D_{50\%}}$$

(4)

where $D_{2\%}$, $D_{50\%}$, and $D_{98\%}$ are the dose values by 2%, 50% and 98% volume of PTV, respectively

2.K | External index (EI)

The external index describes the exposure ratio of health tissue,\textsuperscript{35,42} described as:

$$C_A = \frac{(V_{PI} - PTV_{PI})}{PTV}$$

(5)

where PI is prescription isodose, $V_{PI}$ denotes total tissue volume received prescribed dose and $PTV_{PI}$ denotes planning target volume received prescribed dose.

2.L | Organs at risk dosimetric evaluation

Volume of 20 Gy, 2.5 Gy and mean dose of lungs ($V_{20\%}$, $V_{2.5\%}$, and $D_{mean}$) were investigated. As previously described, the tumors investigated were located in different regions (central, peripheral, different lobes, etc.). The OARs for each lesion differed due to location thus data related to OARs other than lung was insufficient to make comparison between different planning techniques. Since random patients and target locations were chosen, it was statistically insignificant to collect plan acceptance data for spinal cord, heart, esophagus, trachea, chest wall, bronchus, and great vessels to compare, but dose constraints were used in optimization of VMAT plans to achieve acceptable OAR’s limits.

2.M | Statistical analysis

The Shapiro test was used to check whether the parameters were normally distributed. Wilcoxon rank test was performed to compare the dosimetric parameters of DCA, VMAT and DCA with DMD techniques. The tests were statistically significant if $P$ value was $< 0.05$. The errors indicated interpatients’ variability at 1 standard deviation level. Correlation analysis was applied with Spearman Correlation analysis, using SPSS 23 (IBM, New York, NY, USA).

3 | RESULTS

The comparison of mean dosimetric evaluation parameters for DCA-DMD-6FFF, VMAT-6FFF, VMAT-10FFF, DCA-6FFF and DCA-10FFF...
TABLE 3  The dosimetric evaluation results for different techniques. Dosimetric results are the mean of indices ± one standard deviation (SD) for 20 patients.

| Parameter       | DCA-DMD-6FFF | VMAT-6FFF | VMAT-10FFF | DCA-6FFF | DCA-10FFF | P value (DCA-DMD-6FFF vs. others respectively) |
|-----------------|--------------|-----------|------------|----------|-----------|-----------------------------------------------|
| PTV D_{mean} (%)| 116.3 ± 3.81 | 115.6 ± 5.13 | 117.1 ± 4.68 | 120.7 ± 4.01 | 122.8 ± 3.42 | P = 0.60; < 0.01; < 0.001; < 0.001 |
| PTV D_{max} (%) | 131.7 ± 9.00 | 132.9 ± 9.01 | 134.8 ± 8.25 | 135.9 ± 8.40 | 141.5 ± 6.04 | P = 0.13; < 0.02; < 0.001; < 0.001 |
| PTV D_{25%} (%) | 129.7 ± 7.89 | 128.2 ± 7.55 | 131.4 ± 7.42 | 134.1 ± 7.47 | 139.3 ± 5.69 | P = 0.06; < 0.01; < 0.001; < 0.001 |
| PTV D_{95%} (%) | 96.5 ± 0.99  | 96.0 ± 3.91 | 96.1 ± 3.60 | 93.5 ± 2.66 | 93.5 ± 2.20 | P = 0.60; < 0.01; < 0.001; < 0.001 |
| CI              | 1.02 ± 0.02  | 1.060 ± 0.06 | 1.080 ± 0.05 | 1.150 ± 0.07 | 1.180 ± 0.07 | P = 0.002; < 0.01; < 0.001; < 0.001 |
| C_{IPaddick}    | 0.861 ± 0.02 | 0.835 ± 0.05 | 0.823 ± 0.05 | 0.771 ± 0.05 | 0.735 ± 0.04 | P = 0.01; < 0.02; < 0.001; < 0.001 |
| R_{50%} (%)     | 3.99 ± 0.40  | 4.15 ± 0.58  | 4.32 ± 0.66  | 4.17 ± 0.52  | 4.40 ± 0.52  | P = 0.32; < 0.004; = 0.04; < 0.001 |
| D_{2 cm} (%)    | 53.23 ± 9.97 | 57.80 ± 10.83 | 56.91 ± 10.44 | 57.35 ± 10.14 | 58.06 ± 10.77 | P = 0.009; < 0.01; < 0.001; < 0.001 |
| HI              | 0.284 ± 0.06 | 0.276 ± 0.07 | 0.299 ± 0.06 | 0.334 ± 0.07 | 0.371 ± 0.05 | P = 0.57; < 0.46; < 0.001; < 0.001 |
| CA              | 0.085 ± 0.02 | 0.120 ± 0.06 | 0.135 ± 0.05 | 0.207 ± 0.07 | 0.238 ± 0.06 | P = 0.002; < 0.01; < 0.001; < 0.001 |
| MU              | 2254 ± 860   | 3250 ± 1029 | 2994 ± 923  | 2323 ± 897  | 2132 ± 800  | P < 0.001; < 0.01; < 0.001; < 0.001 |
| Lung V_{20 Gy} (%) | 4.19 ± 3.33 | 4.03 ± 3.56 | 4.26 ± 3.63 | 4.36 ± 3.07 | 4.46 ± 3.27 | P = 0.88; < 0.062; < 0.079; < 0.086 |
| Lung V_{2.5 Gy} (%) | 27.88 ± 15.12 | 23.83 ± 13.46 | 25.73 ± 14.21 | 26.23 ± 14.07 | 27.41 ± 14.36 | P < 0.001; < 0.01; < 0.01; < 0.01 |
| MLD (Gy)        | 3.72 ± 2.28  | 3.42 ± 2.03 | 3.52 ± 2.08 | 3.59 ± 2.14 | 3.72 ± 2.25 | P < 0.001; < 0.020; < 0.03; < 0.827 |

are presented in Table 3. All techniques were compared according to mean CI and C_{IPaddick} values, and it was observed that DCA-DMD-6FFF plans demonstrated the best mean CI (1.02 ± 0.02) and C_{IPaddick} (0.861 ± 0.02) values, respectively, compared to VMAT-6FFF (1.06 ± 0.06 and 0.835 ± 0.05), VMAT-10FFF (1.08 ± 0.05 and 0.823 ± 0.05), conventional DCA-6FFF (1.15 ± 0.07 and 0.771 ± 0.05) and DCA-10 FFF (1.18 ± 0.07 and 0.735 ± 0.04) plans. A box plot representation of these finding is shown in Fig. 3. It was observed that both conformity parameters for DCA-DMD-6FFF were statistically significantly compared to other techniques (P = 0.002; < 0.001; < 0.001 for CI and P = 0.01; < 0.02; < 0.001 for C_{IPaddick}).

Intermediate dose spillage parameters (R_{50%}, D_{2 cm}) are also compared for all techniques. Among all, DCA-DMD-6FFF plans achieved the best R_{50%} and D_{2 cm} (3.99% and 53.23%, respectively) values with respect to VMAT-6FFF (4.15% and 57.80%), VMAT-10FFF (4.32% and 56.91%), conventional DCA-6FFF (4.17% and 57.35%), and DCA-10 FFF (4.40% and 58.06%) plans respectively. R_{50%} and D_{2 cm} values were found to be similar to DCA-DMD-6FFF and DCA-DMD-6FFF techniques. (P = 0.32) However, DCA-DMD-6FFF technique achieved statistically significantly better results than others. (R_{50%} = 0.004; = 0.04; < 0.001 for R_{50%} and P = 0.009; < 0.01; < 0.001; < 0.001 for D_{2 cm}). DCA-DMD-6FFF technique improved R50% and D2 cm values 4%, 8%, 4.5%, 10% and 8.5%, 7%, 7.7% respectively.

**Fig. 3.** CI and C_{IPaddick} values for all techniques. Red and blue dashed lines refer to minor and none deviation values of 1.5 and 1.2, respectively.
and 9%, respectively, for the other 4 techniques. Normalized graphs of $R_{50\%}$ and $D_{2 \text{ cm}}$ are shown in Fig. 4. In this graph, it is shown that DCA-DMD-6FFF technique is superior to other techniques in terms of intermediate dose spillage parameters.

All techniques were compared in terms of mean HI. Mean HI was 0.284 ± 0.06 for DCA-DMD-6FFF, 0.276 ± 0.07 for VMAT-6FFF ($P = 0.57$), 0.299 ± 0.06 for VMAT-10FFF ($P = 0.46$), 0.334 ± 0.07 for DCA 6FFF ($P = 0.001$), 0.371 ± 0.05 for DCA-10FFF ($P < 0.001$). There was no statistical significant difference between DCA-DMD-6FFF and VMAT techniques. Conversely, there was a statistically significant difference between DCA-DMD-6FFF and conventional DCA plans in terms of HI. Furthermore, a linear significant negative correlation was found ($P = -0.472$) between HI and volume of PTV for DCA-DMD-6FFF plans. (Data not shown)

$CD$, which is an indicator for the exposure of healthy tissues was also significantly improved by DCA-DMD-6FFF plans with respect to others ($P = 0.002$; $= 0.001$; $< 0.001$). Mean $CD$ was $0.085 ± 0.02$ [0.052-0.140] for DCA-DMD-6FFF plan and $0.120 ± 0.06$ [0.056-0.311] for VMAT-6FFF. Furthermore, strong positive and negative correlations were found between $\Delta$ and $C_{\text{Paddick}}$ at the level of 0.01 ($P = 0.873$, $P = -0.809$, respectively) which are illustrated in Fig. 5. Dose conformity surrounding PTV showed a strong correlation with dose gradient in the

![Fig. 4. Normalized Graphs of $R_{50\%}$ and $D_{2 \text{ cm}}$. All $R_{50\%}$ and $D_{2 \text{ cm}}$ results of other techniques are normalized to the values of DCA 6FFF DMD technique. (a) Normalized $R_{50\%}$ (b) Normalized $D_{2 \text{ cm}}$. Solid line passes from 1.000 which is 3DCA 6FFF DMD.](image)

![Fig. 5. Correlation of $\Delta$ with CI and $C_{\text{Paddick}}$ indexes for DCA-DMD 6FFF plan.](image)
penumbra region. DCA with DMD seemed to improve dose gradient in penumbra region and obtain results comparable to VMAT technique in the vicinity of high dose spillage and intermediate dose spillage regions, as shown in Fig. 6.

As is well known, MUs will be significantly higher for VMAT treatment plans compared to the other techniques. Mean MUs were found to be 2254, 2323, 2132 MU for DCA-DMD-6FFF, DCA-6FFF and 10 FFF, respectively, in this study. Mean MU values were 3250 and 2994 MU for 6FFF and 10FFF of VMAT plans. DCA-DMD-6FFF method reduced MUs 44% and 33% percent with respect to VMAT-6FFF and 10FFF, respectively, (P < 0.001; P < 0.001) without sacrificing dose conformity.

When all techniques were compared in terms of OAR doses, results showed that the lowest V20, V2.5, and MLD values were achieved with VMAT. Nevertheless, there was no statistically significant difference between techniques for V50 values. (VMAT-6FFF; 4.03%, DCA-DMD-6FFF; 4.19%, DCA-6FFF; 4.36%, and DCA-10FFF; 4.46% plans (P = 0.88; = 0.62; = 0.079, respectively. V2.5 and MLD values were statistically more significant with VMAT-6FFF (23.83% and 3.42 Gy, respectively) compared to DCA-DMD-6FFF (27.88% and 3.72 Gy, respectively), DCA-6FFF (26.23% and 3.59 Gy, respectively) and DCA-10FFF (27.41% and 3.72 Gy, respectively) plans. (P < 0.001; = 0.003; < 0.001, respectively, for V2.5 and P < .001; = 0.002; < 0.001, respectively, for MLD).

Currently, VMAT can be considered as an optimal solution with respect to the cost of delivery time.

FFF photon beams permit high dose per pulse through higher dose rate delivery with respect to photon beams obtained with flattening filter. Vassiliev et al.27 were the first to report on the physical feasibility for prototype FFF beams modified from a Clinac for early stage NSCLC. They reported a better dose distribution and reduced treatment time with FFF beams. Hrbacek et al.22 also stated the FFF beams yielded dose distributions similar to flattened beams with significantly reduced treatment delivery time. Viellevigne et al. also showed the dosimetric gain and efficiency advantages of FFF beams over FF for different sizes of PTV from 1.52 cc to 445.24 cc on virtual phantom, lung and liver.20 Thus, a combination of FFF with DCA or VMAT could give optimal SBRT treatment delivery.20,25,26

Several studies concluded that VMAT with or without FFF had superior dosimetric conformity parameters when compared to other treatment techniques.17,18,23,25,27 This advantage came from fluence modulation optimization, with the price of longer treatment planning time and complex quality assurance procedures. Results of this study also have shown that VMAT groups achieve superior dosimetric conformity parameters when compared to conventional DCA groups (Table 3). In the subgroup of FFF energy analysis, VMAT-6FFF results were superior to VMAT-10FFF, conventional DCA-6FFF and 10FFF in terms of CI, CIpaddick, R50%, D2 cm, and Cα. These results are in agreement with previous studies.17,18,20,26,35

However, even though VMAT dosimetric results are superior to conventional DCA, DCA techniques with modifications can give better results than standard 3DC, and may be similar to or better than VMAT plans. Several publications have previously been made on the topic of modified DCA planning.28-32 Ross et al. used a modified DCA by expanding PTV volumes 1 or 3 slices more in the superior-inferior directions only for 20 NSCLC cases.28 The isocenter was placed at the lateral midpoint of couch and vertical midpoint of patient in order to avoid collision during arc rotation. Modified DCA plans improved the CI, CIpaddick, R50%, D2 cc, significantly compared to noncoplanar beam. Shi et al. reported their clinical experience for implementation of modified DCA technique for lung and liver SBRT.29,30 They also showed that modified DCA was useful and easy
to implement. Kim et al. offered a negative margin technique (NMT) in order to improve conventional DCA dose conformity by applying negative margins to PTV in radial directions. They compared NMT conformal arc plans with zero margin DCA plans for 5 lung cases with 20.5–52.3 cc sizes. NMT plans generated better conformity indices compared to standard DCA plans. Ogura et al. reported modification of PTV to optimize dose distribution in DCA plans for large metastatic brain tumors by manually fitting modified PTV to the marginal isodose line. Planning was reperformed in iPlan (v 4.5.1, Brainlab, Feldkirchen, Germany) in this study and 24 metastatic brain tumors greater than 2 cm were planned. DCA plans with modified PTV showed better conformity than nonmodified PTV DCA plans. Nonetheless, the methods used in these previous studies were different from the technique used in our study. In our study, a DCA-DMD method with manual positive or negative deformation of PTV slice by slice in all required directions with respect to hot and cold spot volumes around PTV was used. This method significantly improved dosimetric parameters compared to VMAT and conventional DCA techniques in terms of CI, CI\textsubscript{Pad}	extsubscript{ick}, D\textsubscript{2 cm}, HI, and CA parameters.

Moreover, DCA technique uses MLC-shaped open fields at control point of beam eye view instead of MLC modulation. While dose rate is changed dynamically during beam on in VMAT treatments, maximum constant dose rate can be delivered in DCA. As a result, DCA technique generates lesser MU and shorter delivery time than modulated techniques. In this study, it has been shown that DCA treatments may result in 44% and 37% shorter beam on time than VMAT-6FFF and VMAT-10FFF techniques, respectively.

When OAR doses were compared for different techniques, it was observed that there were better V\textsubscript{20}, V\textsubscript{2.5}, and MLD values for VMAT-6FFF. Optimization and exclusion of uninvolved contralateral lung arc sector appears to reduce the parameters significantly for VMAT technique. These findings were supported by the reportings of Zhang et al. and Navarria et al. However, the results of the Ong et al. study have shown contrary results. RTOG 0915 study guideline recommends using minimum 340° arc sectors for coplanar and noncoplanar DCA techniques in order to create better coverage. Implementation of these recommendations results in increases in V\textsubscript{20}, V\textsubscript{2.5}, and MLD values as expected for DCA.

Reducing delivery time without sacrificing quality of plans is an important goal for departments. This reduction of delivery time necessarily leads to a benefit in terms of cost effectiveness. The new method of DCA introduced in this study makes DCA a simple, fast, and reliable SBRT technique. However, the DCA-DMD technique is dependent on the trial and error method. This method requires delineation and deformation of a new PTV for dose calculation, which can be time consuming. Nevertheless, this time would seem to be less than the optimization and quality assurance process of VMAT.

5 CONCLUSIONS

This study indicates that DCA plans can be improved by using the DMD method. This method overcomes the problems of conventional DCA technique such as hot spot doses adjacent to normal tissue, nonconformal coverage around PTV and hotspot shift out of PTV. Furthermore, DCA with DMD methods lead to similar, if not better, results in terms of dosimetric parameters in comparison to VMAT. It is strongly believed that DCA-DMD is an efficient and cost-effective technique for SBRT plans.

ACKNOWLEDGMENTS

Authors thank Dr. Teuta Zoto Mustafayev and Mr. Patrick Owen for the English revision of the manuscript.

CONFLICT OF INTEREST

The authors have no conflicts of interest.

REFERENCES

1. Guckenberger M, Andratschke N, Alheit N, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190:26–33.
2. Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 2011;50:677–683.
3. Uematsu M, Shioda A, Tahara K. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 82:1062–1070.
4. Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiat Oncol. 57:225–236.
5. Herfarth KK, Debus J, Lohr F, et al. Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys. 46:329–335.
6. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–1076.
7. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:348–353.
8. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk adapted fractionated stereotactic radiotherapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–692.
9. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839.
10. Takeda A, Kunieda E, Sanuki N, et al. Dose distribution analysis in stereotactic body radiotherapy (SBRT) using dynamic conformal multiple arc therapy (DCMAT). Int J Radiat Oncol Biol Phys. 2009;74:363–369.
11. Verbakel W, Senan S, Cuijpers JP, Slotman B, Lagerwaard F. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. Radiat Oncol. 2009;93:122–124.
12. Peterlin P, Stanic K, Mendez I, Strojnik A. Treating lung cancer with dynamic conformal arc therapy: a dosimetric study. Radiat Oncol. 2017;12:93.
13. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of...
inoperable non–small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3d conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57:875–890.

14. Scorsetti M, Navarria P, Mancosu P, et al. Large volume unresectable locally advanced non–small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiat Oncol. 2010;5:94.

15. Kron T, Grigorov G, Yu E, et al. Planning evaluation of radiotherapy for complex lung cancer cases using helical tomotherapy. Phys Med Biol. 2004;49:3675–3690.

16. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35:310–317.

17. Zhang GG, Ku L, Dilling TJ, et al. Volumetric modulated arc therapy for lung stereotactic body radiotherapy using conventional and unflattened photon beams: a dosimetric comparison with 3D technique. Radiat Oncol. 2011;6:152.

18. Ong CL, Verbakel WF, Dahele M, Cuijpers JP, Slotman BJ, Senan S. Fast arc delivery for stereotactic body radiotherapy of vertebral and lung tumors. Int J Radiat Oncol Biol Phys. 2012;83:e137–e143.

19. Scorsetti M, Alongi F, Castiglioni S, et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011;12:113.

20. Vielleveigne L, Bessieres S, Ouali M, Lasanspezee C. Dosimetric comparison of flattened and unflattened beams for stereotactic body radiation therapy: impact of the size of the PTV on dynamic conformal arc and volumetric modulated arc therapy. Phys Med. 2016;32:1405–1414.

21. Kragl G, Wetterstedt S, Knaus B, et al. Dosimetric characteristics of 6 and 10 MV unflattened photon beams. Radiother Oncol. 2009;93:141–146.

22. Hrbacek J, Lang S, Graydon SN, Klock S, Riesterer O. Dosimetric comparison of flattened and unflattened beams for stereotactic ablative radiotherapy of stage I non–small cell lung cancer. Med Phys. 2014;41:031709.

23. Holt A, van Vliet-Vroegindeweij C, Mans A, Belderbos JS, Damen EM. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensity-modulated radiotherapy techniques. Int J Radiat Oncol Biol Phys. 2011;81:1560–1567.

24. Hrbacek J, Lang S, Klock S. Commissioning of photon beams of a flattening filter-free linear accelerator and the accuracy of beam modeling using an anisotropic analytical algorithm. Int J Radiat Oncol Biol Phys. 2011;80:1228–1237.

25. Ong CL, Verbakel WF, Cuijpers JP, Slotman BJ, Cuijpers JP, Slotman BJ, Lagerwaard FJ, Senan S, et al. Negative margin technique - a novel planning strategy to improve dose conformation in SBRT using dynamic conformal arc delivery. J Appl Clin Med Phys. 2013;14:79–89.

26. Radiation Oncology Therapy Group. RTOG 0915. – RTOG0915 (NCT00927) A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules For Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0915

27. Guckenberger M, Baier K, Polat B, et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol. 2010;97:65–70.

28. Ross CC, Kim JJ, Chen ZJ, et al. A novel modified dynamic conformal arc technique for treatment of peripheral lung tumors using stereotactic body radiation therapy. Prat Radiat Oncol. 2011:1:126–134.

29. Shi C, Tazi A, Fang DX, Iannuzzi C. Implementation and evaluation of modified dynamic conformal arc (MDCA) technique for lung SBRT patients following RTOG protocols. Med Dosim. 2013;38:287–290.

30. Shi C, Chen YA, Fang DX, Iannuzzi C. Application of modified dynamic conformal arc (MDCA) technique on liver stereotactic body radiation therapy (SBRT) planning following RTOG 0438 guideline. Med Dosim. 2015;40:26–31.

31. Ogura K, Kosaka Y, Imagimai T, et al. Modifying the planning target volume to optimize the dose distribution in dynamic conformal arc therapy for large metastatic brain tumors. Jpn J Radiol. 2017:35:335–340.

32. Kim S, Kim T, Ko SJ, et al. Negative margin technique - a novel planning strategy to improve dose conformation in SBRT using dynamic conformal arc delivery. J Appl Clin Med Phys. 2013:14:79–89.

33. Radiation Oncology Therapy Group. RTOG 0915. – RTOG0915 (NCT00927) A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules For Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0915

34. Mustakis C, Blanck O, Ebrahimi Tazehmahalleh F, et al. Planning benchmark study for SBRT of early stage NSCLC. Strahlenther Onkol. 2017;193:780–790.

35. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6:2036–2043.

36. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078–4101.

37. Vanetti E, Nicolinì G, Nord J, et al. On the role of the optimization algorithm of RapidArc(®) volumetric modulated arc therapy on plan quality and efficiency. Med Phys. 2011;38:5844–5856.

38. Padick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93:219–222.

39. ICRU. (1999). Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50). J ICRU os32(1):NP (ICRU Report 62).

40. ICRU. (1999). Prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 10(1):NP (ICRU Report 83).

41. Haverkamp U, Norkus D, Kriz J, et al. Optimization by visualization of indices. Strahlenther Onkol. 199:1053–1059.

42. Padick I, Lippitz B. A simple dose gradient measurement tool to complement the conformity index. J Neurosurg. 2006;105:194–201.

43. Feuvret L, Noél G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys. 2006;64:333–342.